BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9755384)

  • 1. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
    Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
    Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.
    Cottin Y; Touzery C; Coudert B; Richebourg S; Cohen M; Toubeau M; Louis P; Wolf JE; Brunotte F
    Eur J Nucl Med; 1996 May; 23(5):511-6. PubMed ID: 8698054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of early epirubicin cardiotoxicity in women with breast cancer.
    Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S
    Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
    Valdés Olmos RA; Carrió I; Hoefnagel CA; Estorch M; ten Bokkel Huinink WW; López-Pousa J; Dalesio O
    Nucl Med Commun; 2002 Sep; 23(9):871-7. PubMed ID: 12195092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular peak filling rate, heart failure and 1-year survival in patients with acute myocardial infarction.
    Gadsbøll N; Høilund-Carlsen PF; Badsberg JH; Lønborg-Jensen H; Stage P; Marving J; Jensen BH
    Eur Heart J; 1991 Feb; 12(2):194-202. PubMed ID: 2044553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.
    Maini CL; Sciuto R; Ferraironi A; Vici P; Tofani A; Festa A; Conti F; Lopez M
    J Nucl Cardiol; 1997; 4(6):502-8. PubMed ID: 9456190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
    Katamadze NA; Lartsuliani KP; Kiknadze MP
    Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of doxorubicin cardiotoxicity by echocardiogram and the appropriate method of using doxorubicin].
    Okada Y; Horikawa K; Makino H; Sano M
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2137-41. PubMed ID: 9388525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines.
    Radulescu D; Pripon S; Radulescu LI; Duncea C
    Acta Cardiol; 2008 Feb; 63(1):27-32. PubMed ID: 18372577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
    Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
    Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
    Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease.
    Constine LS; Schwartz RG; Savage DE; King V; Muhs A
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):897-906. PubMed ID: 9369139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity?
    Patel CD; Balakrishnan VB; Kumar L; Naswa N; Malhotra A
    Hell J Nucl Med; 2010; 13(3):233-7. PubMed ID: 21193876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
    Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
    J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.